451 related articles for article (PubMed ID: 22108203)
1. PET amyloid-beta imaging in preclinical Alzheimer's disease.
Vlassenko AG; Benzinger TL; Morris JC
Biochim Biophys Acta; 2012 Mar; 1822(3):370-9. PubMed ID: 22108203
[TBL] [Abstract][Full Text] [Related]
2. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
4. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
[TBL] [Abstract][Full Text] [Related]
5. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
6. Secondary prevention of Alzheimer's dementia: neuroimaging contributions.
Ten Kate M; Ingala S; Schwarz AJ; Fox NC; Chételat G; van Berckel BNM; Ewers M; Foley C; Gispert JD; Hill D; Irizarry MC; Lammertsma AA; Molinuevo JL; Ritchie C; Scheltens P; Schmidt ME; Visser PJ; Waldman A; Wardlaw J; Haller S; Barkhof F
Alzheimers Res Ther; 2018 Oct; 10(1):112. PubMed ID: 30376881
[TBL] [Abstract][Full Text] [Related]
7. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL; Rowe CC
J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.
Mosconi L; Berti V; Glodzik L; Pupi A; De Santi S; de Leon MJ
J Alzheimers Dis; 2010; 20(3):843-54. PubMed ID: 20182025
[TBL] [Abstract][Full Text] [Related]
10. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J
Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
13. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
14. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.
Scheinin NM; Scheinin M; Rinne JO
Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):265-79. PubMed ID: 21532540
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
[TBL] [Abstract][Full Text] [Related]
16. [Amyloid PET in Alzheimer research].
Ishii K
Brain Nerve; 2010 Jul; 62(7):757-67. PubMed ID: 20675880
[TBL] [Abstract][Full Text] [Related]
17. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
[TBL] [Abstract][Full Text] [Related]
18. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
20. Subthreshold Amyloid Predicts Tau Deposition in Aging.
Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
